Why Gilead Sciences, Inc. (GILD) stock moved
Gilead Sciences, Inc. (GILD) shares rose 4.0% to $165.61 as of October 29, 2026, a moderate gain from the prior close of $159.20. BestStocks flagged the session as a major change for GILD. The move is tied to an earnings beat. Below, we break down what changed for GILD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Gilead Sciences, Inc. (GILD) reported EPS of $2.55 vs. consensus estimate of $2.19 for Q3 FY2026, beating consensus by 16.4%. Monitor fourth-quarter guidance and any commentary on full-year 2026 results when disclosed.
What it means for Gilead Sciences, Inc. investors
For Gilead Sciences, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 4.0% session move. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in GILD's fundamentals. Wall Street's consensus price target sits at $156.67, implying -5.4% downside from $165.61. BestStocks rates the overall signal quality high (81/100). With earnings roughly 103 days out, the next report is the most likely near-term test of the move.
GILD price reaction
GILD last traded at $165.61, up $6.41 (+4.03%) from the previous close of $159.20. The session traded on 1.3× average volume (normal), so participation was unremarkable. Its healthcare peer group moved a median +1.7% over the same stretch, leaving GILD ahead of the group by 2.3 points. Over the past month the stock has ranged between $144.23 and $165.61, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Gilead Sciences, Inc. (GILD)
The consensus analyst price target on Gilead Sciences, Inc. (GILD) is $156.67, 5.4% below the recent $165.61. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on GILD line up.
The bullish case
- The Street's most bullish target is $185.00 (+11.7%).
- Earnings beat with positive market reaction.
- Positive 4.0% session move.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $156.67 sits 5.4% below the recent $165.61, so the average target sees limited room to run.
- The most bearish analyst target is $126.00 (-23.9%).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for GILD
Frequently asked questions about GILD
Why did Gilead Sciences, Inc. (GILD) stock move?
GILD rose 4.0% to $165.61. The move is associated with an earnings beat and looks like a sector-wide move.
How much did GILD stock rise?
GILD gained 4.03% ($6.41) versus the prior close of $159.20, last trading at $165.61 on 1.3× average volume.
When is Gilead Sciences, Inc.'s next earnings date?
GILD's next earnings report is estimated for 2027-02-09 — about 103 days away.
What is the analyst price target for GILD?
The consensus analyst price target for GILD is $156.67, about 5.4% below the current $165.61. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.
Is the GILD move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +1.7% against GILD's +4.0%. GILD ranks top 2 of 7 peers.
How BestStocks tracks GILD
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for GILD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.